New hope for AML patients: experimental drug IPN60340 enters key trial

NCT ID NCT07623187

Not yet recruiting Disease control Sponsor: Ipsen Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether adding the experimental drug IPN60340 to standard medicines (azacitidine and venetoclax) helps more people with newly diagnosed acute myeloid leukemia (AML) achieve complete remission. About 450 adults who cannot have intensive chemotherapy will take part. The trial is double-blinded, so neither participants nor doctors know who gets IPN60340 or a placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IPN60340 (a biologic drug given by IV) plus azacitidine and venetoclax
What this could lead to: If it works, this could improve remission rates for people with acute myeloid leukemia who cannot handle strong chemotherapy.
What could go wrong: This is an early-to-mid-stage trial with 450 participants. The drug may not work better than placebo, and side effects from the combination could be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKAEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloblastic leukemia with maturation acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKAEMIA ACUTE MYELOID LEUKAEMIA (AML)

More trials for these conditions

Other studies related to the condition(s) this trial covers.